SCHEMBL3585067

SCHEMBL3585067

CN(CCSc1ccc(CC(=O)O)cc1Cl)c1cccc(N(C)CCSc2ccc(CC(=O)O)cc2Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 10/20 0.42
PPARG P37231 8/20 0.41
PPARA Q07869 8/20 0.41
CA2 P00918 1/20 0.41
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
DGAT1 O75907 2/20 0.37
SOAT1 P35610 2/20 0.37
SLC22A12 Q96S37 2/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
CNR1 P21554 1/20 0.36
LTB4R Q15722 2/20 0.36
LTB4R2 Q9NPC1 2/20 0.36
AR P10275 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542377 0.86 HTR7 (0.37) SLC22A12CNR1
SCHEMBL3532524 0.81 PRKAG1 (0.41) PRKAG1PRKAA2PRKAB1LTB4RLTB4R2
SCHEMBL3533830 0.81 PPARA (0.42) PPARDPPARGPPARA
SCHEMBL3532536 0.81 SLC6A4 (0.39) CA2DGAT1LTB4RLTB4R2
SCHEMBL3538793 0.77 LTB4R (0.53) PPARDPPARGPPARACA2NR1H2
SCHEMBL3539135 0.71 LTB4R (0.49) PPARDPPARGPPARANR1H2NR1H3
SCHEMBL2162178 0.70 CA2 (0.59) PPARDPPARGPPARACA2DGAT1
SCHEMBL4031971 0.70 CA2 (0.51) PPARDPPARGPPARACA2LTB4R
SCHEMBL3532519 0.70 PRKAG1 (0.34) PRKAG1PRKAA2PRKAB1CNR1
SCHEMBL3531507 0.69 PLA2G4B (0.50) PPARDPPARGPPARANR1H3LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP claimed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US claimed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO claimed
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP disclosed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US disclosed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259950-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD PPARD 3/4885PPARG 1/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.